Crinetics Pharmaceuticals (CRNX) Non-Current Deffered Revenue (2017 - 2026)

Crinetics Pharmaceuticals' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 22.42% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $3.3 million, a 22.42% decrease from a year earlier, with the FY2025 full-year figure at $3.8 million, down 19.01% from the prior year.
• Non-Current Deffered Revenue slipped to $3.3 million in Q1 2026 per CRNX's latest filing, from $3.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $7.2 million in Q1 2022 and bottomed at $3.3 million in Q1 2026.
• The 5-year median for Non-Current Deffered Revenue is $4.8 million (2023), against an average of $5.1 million.
• Across the five-year window, Non-Current Deffered Revenue surged 94928.57% in 2022 and slipped 26.36% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $6.1 million in 2022, then fell by 22.14% to $4.8 million in 2023, then declined by 0.97% to $4.7 million in 2024, then fell by 19.01% to $3.8 million in 2025, then slipped by 12.18% to $3.3 million in 2026.
• Per Business Quant, the three latest CRNX Non-Current Deffered Revenue figures stand at $3.3 million (Q1 2026), $3.8 million (Q4 2025), and $4.1 million (Q3 2025).